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Abstract: Methimazole (MMI) is often the selected medical treatment for feline hyperthyroidism.
However, the onset of MMI-related side effects (MMI-SE) is likely caused by oxidative stress. This study
evaluated the dietary supplementation of selected antioxidants in hyperthyroid cats receiving MMI,
to reduce MMI-SE. Thirty hyperthyroid client-owned cats were randomly allocated in group M (MMI
+ placebo) or group M+A (MMI + antioxidants). At different time-points from the enrolment (ET) to
the end of the trial (FT), the following information was recorded: clinical findings, complete blood
count, serum biochemical parameters, urinalysis, total plasma thyroxine concentrations, determinable
reactive oxygen metabolites (dROMs), OXY-adsorbent test values, and oxidative stress index (OSi)
values, and MMI-SE. dROMs and OSi values significantly increased from ET to FT in group M and
were significantly higher in group M than in group M+A at FT. Likewise, OXY-absorbent test values
were significantly higher in group M+A than in group M at FT. Moreover, the occurrence rate of
MMI-SE in group M+A was lower than in group M. In conclusion, our results show that the dietary
supplementation of antioxidants in hyperthyroid cats receiving MMI exerts a protective effect against
oxidative stress, likely contributing to the reduction of MMI-SE.
Keywords: antioxidants; quercetin; curcumin; resveratrol; vitamin E; redox unbalance; feline
hyperthyroidism; methimazole
1. Introduction
Feline hyperthyroidism is the most common endocrinopathy in middle-aged and geriatric cats
sharing clinical, pathological, and therapeutic similarities with the human disease. As such, it offers a
unique animal model for the study of human hyperthyroidism. [1]. Moreover, both species are at risk
of developing redox unbalance during the disease course [2,3]. Previously, it has been demonstrated
that hyperthyroid cats display impairment of the antioxidant status (AS) compared to both healthy
cats and cats suffering from chronic non-thyroidal illnesses. Thus, they represent an ideal patient
group for antioxidant supplementation [4]. Although non-curative, methimazole (MMI) is the medical
treatment of choice for most hyperthyroid cats [5]. Unfortunately, the occurrence of MMI-related side
effects (MMI-SE), such as hepatotoxicosis, gastrointestinal upset, vasculitis, facial pruritus, and blood
dyscrasias, could hinder the attainment of euthyroidism. The onset of MMI-SE is correlated to an
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increase in oxidative stress (OS) markers in both humans and animal models [6]. Indeed, MMI
metabolism generates intermediate reactive compounds, such as N-methyl thiourea and glyoxal,
that can act as pro-oxidants both at cellular and tissue level [6,7]. Field studies in veterinary medicine
are scattered, and clinical trials evaluating the effect of antioxidant supplementation during MMI
treatment of hyperthyroid cats are lacking.
Among antioxidants, curcumin is one of the most used and effective hepato-protectant agents;
resveratrol is able to ameliorate cardiovascular health [8,9]; quercetin inhibits thyroid type 1 deiodinase
activity, and improves intestinal absorption and bioavailability of both curcumin and resveratrol [10,11];
and vitamin E plays a major role in destroying peroxyl radicals, thus protecting polyunsaturated
fatty acids biological membranes from oxidative damage [12]. The concomitant supplementation of a
mixture of such compounds in hyperthyroid cats receiving MMI could improve their clinical outcome
and redox unbalance, reducing the risk of hepatic, cardiac, renal, and hematological alterations,
elicited by both the disease itself and the antithyroid drug administration [13]. Thus, our study was
designed first to evaluate the potential synergistic effect of curcumin, quercetin, resveratrol, and
vitamin E as an additional treatment for hyperthyroid cats receiving MMI, and then to assess the
capability of such molecules to reduce the occurrence of MMI-SE.
2. Materials and Methods
This study represents phase II of a previous research project [4]. All clinical maneuvers were
performed in strict accordance with AAFP (American Association of Feline Practitioners) and ISFM
(International Society of Feline Medicine) Feline-Friendly Handling Guidelines [14], were approved
by the local bioethical committee of Turin University (EC 2017/42bis), and carried out in accredited
ISFM Cat Friendly Clinics or in cat-friendly environments. All efforts were made to minimize animal
discomfort. A written informed consent to participate was obtained from all cat owners. The study
design is depicted in Figure 1.
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2.1. Animals and Inclusion Criteria
From December 2017 to July 2018, newly diagnosed hyperthyroid cats presented to the Veterinary
Teaching Hospital of the University of Turin and other referral clinics throughout Northern Italy
were enrolled. Inclusion criteria were total plasma thyroxine (tT4) concentrations > 54 nmol/L or
4.3 µg/dL, as previously described, and owner agreement to administer the treatments and to attend
all the scheduled appointments during the study [4]. Exclusion criteria were concurrent systemic
diseases, such as congestive heart failure, renal failure (IRIS Stage 3 or 4) [15], systemic neoplasia,
chronic liver disease, immune-mediated disease, or systemic infection [16], suspected nutritional
deficiencies, antioxidant supplementation within 3-months, and administration of iodine-restricted
food or commercial diet enriched with patented antioxidant formula [4].
2.2. Antioxidant Supplementation and Medical Treatment
Before starting the study, two sets of identical 15-mL graduated tube-syringes containing either
a lipophilic emulsion (paste) of antioxidants (curcumin, quercetin, resveratrol, and vitamin E) or a
lipophilic vehicle with a yellow inert pigment to mimic curcumin color (placebo) were commissioned
from a sponsor company (DogPower, Novara, Italy). Antioxidants and their concentrations were
selected according to the results obtained in previous in vitro experiments [17]. The composition of the
antioxidant paste is reported in Table 1.
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Table 1. Composition of the 15-mL syringe containing the antioxidant mixture formulated as a paste.
Antioxidant Compound * Dose in 1mL of Paste
Curcumin 100 mg
Quercetin 40 mg
Resveratrol 1.5 mg
Vitamin E 15 mg
* Inactives: sunflower oil, malt, soybean oil, glyceryl stearate, lecithin e322.
A double-blind study was performed dividing hyperthyroid cats into two treatment groups: one
receiving MMI and placebo (group M), and one receiving MMI and antioxidants (group M+A). The
allocation of animals into the two groups was performed by using a computer-generated random
list (Microsoft Excel, Office 2011, Microsoft Corporation, Redmond, WA, USA). All cats were orally
administered 1 mL/4 Kg/day of either placebo (group M) or the antioxidant paste (group M+A).
From the enrolment (enrolment time, ET), each cat was monitored for 180 days (finish time, FT),
with intermediate screenings after 15 (T1), 30 (T2), and 90 (T3) days, respectively, according to
Daminet et al. [5].
All cats received a starting dose of 2.5 mg/animal MMI PO, administered twice daily. Drug dosing
adjustments of 25%–50% increase or decrease were performed from T1 to FT, to obtain both plasma
tT4 concentrations in the range of 1.0–2.8 µg/dL, and a proper control of clinical signs. Plasma tT4
concentrations were rechecked 2–3 weeks after every dosing adjustment.
2.3. Standardized Monitoring of Clinical Signs and Symptoms and MMI-SE
At ET, history and clinical findings were recorded through two ad hoc questionnaires, owner’s
hyperthyroid cat clinical score (OHCCS) and veterinarian’s hyperthyroid cat clinical score (VHCCS),
respectively (Tables S1 and S2). Briefly, the determination of body condition score (BCS) was assigned
by considering the WSAVA 1–9 scoring system [18]. Feline body mass index (fBMI) was calculated by
measuring the cat’s rib cage circumference (cm) and the lower back leg length (cm), from the knee to
the ankle. Measures were then inserted into the “Cat’s Health—feline BMI App.” (mobile application
for Windows Phone 8.1), and fBMI was automatically calculated. Modified semi-quantitative thyroid
palpation was performed as previously reported [19]; non-invasive blood pressure measurement by
using an oscillometric device (PetMap Plus+, Vetefarma, Madonna dell’Olmo, IT) was performed
three times for each patient. To assess evidence of hypertensive retinopathy, ophthalmic examination
by indirect ophthalmoscopy, was scheduled if systemic blood pressure (sBP) was >160 mmHg and
diastolic blood pressure (dBP) was >100 mmHg. Blood samples were collected by jugular venipuncture
for the evaluation of complete blood count (CBC), selected serum biochemical parameters (i.e., alanine
aminotransferase, ALT; alkaline phosphatase, ALP; aspartate aminotransferase, AST; blood urea
nitrogen, BUN; creatinine and phosphate) and plasma tT4 concentrations (IDEXX Catalyst One analysis,
Milano, IT), as previously suggested [5]. Standard urinalysis (i.e., urine specific gravity, USG; dipstick
analysis; sediment examination) was also performed.
From T1 to FT, MMI-SE were recorded by an ad hoc standardized questionnaire (side effects
of methimazole treatment questionnaire, SEMT) (Table S3). In addition, CBC, the aforementioned
biochemical parameters, and plasma tT4 concentrations were also monitored. The occurrence of liver
dysfunction and hematological abnormalities was assessed by using VCOG-CTCAEv 1.0 guidelines [20].
In detail, hepatic toxicity was defined as moderate or severe if ALT measurement was ≥1.5–2.0 × ULN
(upper limit of normal) or >2.0 × ULN, respectively, in association with moderate to severe clinical
signs of hepatic dysfunction. Hematological abnormalities, such as neutropenia, thrombocytopenia,
hemolytic anemia, and agranulocytosis, were considered only if severe clinical signs, related to blood
dyscrasia, were detected.
Redox unbalance was determined from ET to FT by measuring determinable reactive oxygen
metabolites (dROMs), OXY-adsorbent test values, and the oxidative stress index (OSi), as previously
Antioxidants 2020, 9, 15 5 of 11
described [4]. All assays were purchased from Diacron International Srl (Grosseto, Italy). Briefly,
d-ROMs were used as an indicator of oxidative stress due to free radicals, while the OXY-adsorbent
test was used to quantify the plasma barrier against oxidation. The oxidative stress index (OSi) was
calculated by the ratio of the dROMs test values to the OXY-adsorbent test values.
2.4. Statistical Analysis
To evaluate the differences between cats of group M and M+A for the nominal data (gender and
breed) and ordinal data (BCS, OHCCS, VHCCS, and SEMT questionnaire scores), descriptive statistics
analysis and the Pearson χ2 test were used. As regards SEMT scores, mild side effects were arbitrarily
defined as scores ranging from 1 to 8 out of 25, moderate side effects from 9 to 16 out of 25, and severe
side effects >17. At ET, differences between the two groups with respect to age, body weight, and USG
were checked by t-test. Differences between the two groups at all time-points for CBC, the selected
biochemical parameters, plasma tT4 concentrations, dROMs, OXY-adsorbent test values, OSi values,
OHCCS, and VHCCS were tested by two-way ANOVA for repeated measures followed by Sidak’s
post-hoc analysis considering all possible comparisons. All statistical analyses were performed using
the software IBM SPSS V.20 (New York, NY, USA) and GraphPad Prism v7 (La Jolla, San Diego, CA,
USA). Values of p ≤ 0.05 were considered statistically significant.
3. Results
Thirty-four cats were enrolled in the study. Four animals were excluded before the end of the
trial due to either an intermittent administration of the treatment (n = 2; from group M+A) or the
lack of compliance with the periodic controls (n = 2; from group M). Of the total 30 hyperthyroid
cats that fulfilled the inclusion criteria, 14 were assigned to group M and 16 to group M+A. At ET,
breed and gender distribution was homogeneous between groups and no statistically significant
differences emerged with respect to age, body weight, BCS, OHCCS, VHCCS, CBC, selected biochemical
parameters, USG, and redox unbalance (Table 2). In particular, average age of animals was equal to
12.8 and 12.9 years in group M and group M+A, respectively.
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Table 2. Clinical pathological variables in hyperthyroid cats of group M (MMI + placebo) and group M+A (MMI + antioxidants) at ET. Values are expressed as mean
values ± standard deviation (SD).
Clinical pathological Features Parameters Group M (n = 14) Group M+A (n = 16) Reference Interval
Signalment
Age (years) 12.8 ± 2.4 12.9 ± 2 /
Breed (n) DSH 9; DLH 3; PERS 1; CHART 1 DSH 11; DLH 1; PERS 1 /
Gender (n) MC 6; FN 8 MC 6; FN 10 /
Body Weight (kg) 3.9 ± 0.7 4.0 ± 0.8 /
BCS 4 ± 0.5 4 ± 0.5 0-9
Hemato-biochemical values
RBC (×106 /uL) 6.6 ± 1.3 6.5 ± 1.1 4.6–10
Htc (%) 34.2 ± 6.7 31.6 ± 6.2 28–49
WBC (×103 /uL) 11.5 ± 5.3 11 ± 4.5 5.5–19.5
Alb (g/dL) 3 ± 0.8 3.3 ± 0.8 2.2–4.4
BUN (mg/dL) 22.7 ± 5.8 23 ± 5.8 10–30
CREA (mg/dL) 1.3 ± 0.3 1.3 ± 0.3 0.3–1.6
ALT (UI/L) 93.7 ± 23 92.1 ± 22.1 20–100
AST (UI/L) 89 ± 27 91 ± 18 10–100
ALP (UI/L) 42 ± 8.4 39 ± 9.6 10–50
Phos (mg/dL) 4.8 ± 1.5 5 ± 1.9 2.4–8.2
Urinary SG 1039 ± 14 1041 ± 12.1 >1035
Thyroid function tT4 (µg/dL) 10 ± 3.4 10.3 ± 3.7 0.8–4.3
Clinical scores OHCCS 16.1 ± 7.4 16.4 ± 7.4 0–35VHCCS 12.1 ± 4 12.6 ± 5.7 0–30
Redox unbalance
dROMs (CarrU) 175.8 ± 2.2 175.3 ± 2.6 <104 *
OXY-Adsorbent (µmol HClO/mL) 301.4 ± 84 321 ± 115 >390 *
OSi (CarrU/µmol HClO/mL) 0.66 ± 0.3 0.66 ± 0.3 <0.27 *
Alb: albumin; ALP: alkaline phosphatase; ALT: alanine aminotransferase; AST: aspartate aminotransferase; BCS: body condition score; BUN: blood urea nitrogen; CHART: Chartreux;
CREA: creatinine; DLH: domestic longhair cat; DSH: domestic shorthair cat; ET: enrollment time; FN: neutered female; GLU: glucose; Htc: hematocrit; MC: male castrated; OHCCS:
owner’s hyperthyroid cat clinical score; PERS: Persian; Phos: phosphate; RBC: red blood cells; SD: standard deviation; SG: specific gravity; tT4: plasma total tetraiodothyroxine; VHCCS:
veterinarian’s hyperthyroid cat clinical score; WBC: white blood cells. *see [4].
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Similarly, statistically significant differences between the two groups in the mean plasma tT4
concentrations were not detected at any time-points. The values rapidly decreased to approximately 3
µg/dL (proper control of the disease) at T1 (p < 0.001 compared to ET) and remained almost unchanged
until FT in all the cats (Figure 2). However, slight fluctuations of plasma tT4 concentrations were
recorded in group M+A compared to group M throughout the study. Moreover, a lower MMI mean
dose was administered to cats of group M+A compared to cats of group M (2.6 ± 0.6 mg/animal/twice
daily vs. 3.3 ± 1.1 mg/animal/twice daily, respectively). Although not statistically significant, ALT
values were more stable during time and across patients in group M+A than in group M, where some
cats showed a moderate increase at FT (91.4 ± 25.8 IU/L vs. 121 ± 46.9 IU/L in group M, respectively.
p = 0.052).
Antioxidants 2019, 8, x FOR PEER REVIEW 7 of 11 
Similarly, statistically significant differences between the two groups in the mean plasma tT4 
concentrations were n t d tect d at ny time-points. The values rapidly decreased to approximately 
3 µg/dL (proper control of the disease) at T1 (p < 0.001 c mpared to ET) and remained almost 
unchanged until FT in all th  cats (Figure 2). However, slight fluctuations of plasma tT4 
c ncentrations were rec rded in     group M throughout the study. Moreover, 
a lower MMI mean dose was administered to cats of group M+A compared to ts of roup M (2.6 ± 
0.6 mg/animal/twice daily vs. 3.3 ± 1.1 mg/animal/twice daily, respectively). Although not statistically 
significant, ALT values were more stable during time and across patients in group M+A than in group 
M, where some cats showed a moderate increase at FT (91.4 ± 25.8 IU/L vs. 121 ± 46.9 IU/L in group 
M, respectively. p = 0.052). 
 
Figure 2. Total plasma T4 (tT4) concentrations in hyperthyroid cats receiving methimazole and 
placebo (group M, n = 14), or methimazole and antioxidants (group M+A, n = 16). Asterisks indicate 
statistically significant differences compared to ET (*** p < 0.001). Statistical analysis was performed 
by two-way ANOVA for repeated measures followed by Sidak’s post-hoc test. ET = enrollment time; 
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All data about redox unbalance (dROMs and OSi tests) and antioxidant capacity (OXY-adsorbent
test) are summarized in Figure 3.
In detail, dROMs values progressively increased in group M up to 1.7-fold at FT, being statistically
significant at all time-points compared to ET (p < 0.001). On the contrary, group M+A displayed a
significant and time-dependent reduction of dROMs values up to 2.3-fold at FT (at least p < 0.01). Such
a divergent temporal trend of free radicals production between groups was significantly related to
treatment (p < 0.001 at all time-points). Consistently, OXY-adsorbent test values significantly increased
only in group M+A (p < 0.001) and were significantly different from group M at all time-points (p < 0.05).
As a consequence, OSi test results indicated an increase in oxidative stress in the M group compared
to M+A at all time-points (at least p < 0.01). When considering OHCCS and VHCCS questionnaire
scores, both groups showed a significant reduction of OHCCS and VHCCS from ET to FT (at least
p < 0.01), with a significant difference between groups only at T1 (p < 0.05) (Figure 4). The occurrence
rate of MMI-SE in group M+A was lower (12.5%) than in group M (35.7%). Indeed, five cats out of 14
exhibited at least one MMI-SE during the 180-days trial in the group M, compared to only two cats
out of 16 in the group M+A. Only mild idiosyncrasies were recorded during both treatment protocols
(100% of mild MMI-SE in group M+A vs. 80% of mild MMI-SE in group M).
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Figure 4. Owner’s hyperthyroid cat clinical score (OHCCS) (a) and veterinarian’s hyperthyroid cat
clinical score (VHCCS) scores (b) in hyperthyroid cats receiving methimazole and placebo (group
M, n = 14), or methimazole and antioxidants (group M+A, n = 16). Asterisks indicate statistically
significant differences compared to ET (** p < 0.01 and *** p < 0.001). Hashtags indicate statistically
significant differences compared to group M (# p < 0.05). Statistical analysis was performed by two-way
ANOVA for repeated measures followed by Sidak’s post-hoc test. ET = enrollment time; T1 = 15 days;
T2 = 30 days; T3 = 90 days; FT = finish time (180 days).
4. Discussion
To the best of the authors’ knowledge, this study is the first clinical trial reporting the synergistic
effect of a mixture of selected antioxidants as an additional treatment for hyperthyroid cats receiving
MMI. Further, the potential ability to reduce the occurrence of MMI-SE is also considered.
Recently, it was demonstrated that hyperthyroid cats show an increased OS and a greater
impairment of antioxidant capacity in comparison with healthy cats and cats diagnosed with chronical
non-thyroidal illnesses. Moreover, it was proposed that hyperthyroid cats may serve as a spontaneous
animal model for OS-related studies linked to thyrotoxicosis, representing an ideal cohort for nutritional
and antioxidant interventions [4]. Although the link between MMI-SE and redox unbalance has been
acknowledged in both humans and laboratory animal models [6,7], comparative studies in domestic
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species are scarce. Signalment, thyroid status, and hemato-biochemical values of cats of the present
trial were consistent with previous data [13,16]. With respect to the OS induced by hyperthyroidism,
our findings were consistent with previous studies both in veterinary and human medicine [2,4].
On the contrary, the only trial investigating the redox status of hyperthyroid cats before and after
radioiodine treatment did not show any AS impairment irrespective of therapy [16]. However, it
must be noted that the investigated parameters (i.e., reduced GSH, ascorbate, vitamin A, and vitamin
E) mirrored only a fraction of the antioxidant plasmatic barrier, which is actually assessed by the
OXY-adsorbent test. Moreover, the only investigated OS marker was the urinary isoprostanes level,
which resulted significantly increased in hyperthyroid cats and was normalized upon treatment. No
association was found between OS and prior idiosyncratic MMI toxicosis [16]. In our study, both groups
of hyperthyroid cats were experiencing redox unbalance at recruitment (mean OSi value of group
M and group M+A at ET: 0.66 ± 0.3 CarrU/µmol HClO/mL); such condition worsened in patients
receiving MMI alone (mean OSi value of group M at FT: 1.01 ± 0.5). These results suggest that the
redox unbalance could be induced not only by the thyroid dysfunction but also by the administration
of MMI itself. Indeed, in group M+A, the attainment of the euthyroid state was paralleled by both
a progressive decrease in dROMs values at all time-points and a slight increase in OXY-Adsorbent
test values at T1, which remained constant until the end of the study (on average around 470 µmol
HClO/mL). T1 can be considered a sort of “watershed” moment in the fluctuation of AS markers in
both group M and group M+A (Figure 4). Noteworthy, the onset of MMI-SE is usually described from
2 to 6 weeks after the beginning of the treatment [5,21–25]. Interestingly, the increase in dROMs and
OSi levels in group M occurred at the same time point, when it is also likely that the production of
MMI reactive metabolites challenges the endogenous antioxidant defenses. Thus, the antioxidant
supplementation might represent a supportive intervention to reduce the progressive deterioration of
the endogenous antioxidant barrier.
The occurrence of MMI-SE in the present study was relatively higher in both groups (35.7% in
group M and 12.5% in group M+A) compared to a previous trial [21]. However, it should be noted
that the MMI-SE were mostly mild or moderate, and mainly related to occasional gastrointestinal
signs (such as vomiting or diarrhea) and lethargy, rather than life-threatening complications. The
relative overestimation of drug-adverse reactions can be explained by the accurate and standardized
monitoring that could have highlighted events otherwise unnoticed. Although studies reporting a
standardized evaluation of clinical signs and findings are lacking, the OHCCS and VHCCS results
underlined that MMI alone or in association with antioxidants is efficient in reducing clinical symptoms
of thyrotoxicosis in both groups, with a slight better clinical outcome in group M+A.
The MMI dose administered to all cats is in the range reported by other authors [24,25]. However,
group M+A received a lower MMI mean dose compared to group M. A possible explanation of such
phenomenon might be related to quercetin, one of the antioxidants contained in the mixture, reported to
inhibit thyroid peroxidase (TPO) iodination in vitro and to modulate several enzymes involved in the
synthesis and catabolism of thyroid hormones [26].
Although all the commercial diets administered to the cats were checked for both the nutritional
adequacy and the lack of antioxidant patented formula in their composition, the study was performed
with an unstandardized diet. Moreover, precise levels of vitamin E (usually used as a preservative) were
not measured, assuming that they were within FEDIAF suggested requirements [27]; thus, different
intake between the two groups could not be excluded. Nevertheless, the level of supplementation
adopted in the present study was around 4-fold the minimum requirements; thus, vitamin E levels
fluctuation due to different dietary uptakes is reasonably irrelevant.
5. Conclusions
In conclusion, we report here that a mixture of antioxidants, namely curcumin, quercetin,
resveratrol, and vitamin E, can be efficiently administered to hyperthyroid cats to exert a synergistic
effect with MMI. The amelioration of the clinical pathological outcome likely results from both the
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rebalancing of the redox status impaired by the disease, and the reduction of MMI-SE through the
restoration of the antioxidant plasmatic barrier. However, additional studies with a higher number of
animals are needed to further explore the role of antioxidant dietary supplementation in the treatment
of feline hyperthyroidism.
Supplementary Materials: The following are available online at http://www.mdpi.com/2076-3921/9/1/15/s1,
Table S1: Standardized questionnaire formulated ad hoc for the evaluation of clinical signs and symptoms
of hyperthyroid cats, as reported by the owner (Owner Hyperthyroid Cat Clinical Score, OHCCS), Table S2:
Standardized questionnaire formulated ad hoc for the evaluation of clinical signs and symptoms of hyperthyroid
cats, as reported by the veterinarian (Veterinarian Hyperthyroid Cat Clinical Score, VHCCS), Table S3: Standardized
questionnaire formulated ad hoc for the evaluation of MMI-related side effects (Side Effects of Methimazole
Treatment, SEMT).
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